Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/150880COMPARTIR / EXPORTAR:
 SHARE
 CORE
BASE
|
|
| Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
| Título: | The truncated somatostatin receptor sst5TMD4 stimulates the angiogenic process and is associated to lymphatic metastasis and disease-free survival in breast cancer patients |
Autor: | Gahete, Manuel D.; Durán-Prado, Mario; Hergueta-Redondo, Marta CSIC; Moreno-Bueno, Gema CSIC ORCID; Luque, Raúl M.; Castaño, Justo P. | Palabras clave: | Breast cancer VEGF Angiogenesis sst5TMD4 Somatostatin receptor |
Fecha de publicación: | 2016 | Editor: | Impact Journals | Citación: | Oncotarget 7(37): 60110-60122 (2016) | Resumen: | The truncated somatostatin receptor sst5TMD4 is associated with poor prognosis in breast cancer and increases breast cancer cell malignancy. Here, we examined the cellular/molecular mechanisms underlying this association, aiming to identify new molecular tools to improve diagnosis, prognosis or therapy. A gene expression array comparing sst5TMD4 stably-transfected MCF-7 cells and their controls (empty-plasmid) revealed the existence of profound alterations in the expression of genes involved in key tumoral processes, such as cell survival or angiogenesis. Moreover, sst5TMD4- overexpressing MCF-7 and MDA-MB-231 cells demonstrated increased expression/ production of pro-angiogenic factors and enhanced capacity to form mammospheres. Consistently, sst5TMD4-expressing MCF-7 cells induced xenografted tumors with higher VEGF levels and elevated number of blood vessels. Importantly, sst5TMD4 was expressed in a subset of breast cancers, where it correlated with angiogenic markers, lymphatic metastasis, and reduced disease-free survival. These results, coupled to our previous data, support a relevant role of sst5TMD4 in the angiogenic process and reinforce the role of sst5TMD4 in breast cancer malignancy and metastatic potential, supporting its possible utility to develop new molecular biomarkers and drug therapies for these tumors. | Descripción: | Gahete et al. | Versión del editor: | https://doi.org/10.18632/oncotarget.11076 | URI: | http://hdl.handle.net/10261/150880 | DOI: | 10.18632/oncotarget.11076 | Identificadores: | doi: 10.18632/oncotarget.11076 e-issn: 1949-2553 |
| Aparece en las colecciones: | (IIBM) Artículos |
Ficheros en este ítem:
| Fichero | Descripción | Tamaño | Formato | |
|---|---|---|---|---|
| sst5TMD4.pdf | 7,01 MB | Adobe PDF |  Visualizar/Abrir |
CORE Recommender
PubMed Central
Citations
8
checked on 10-abr-2024
SCOPUSTM
Citations
16
checked on 18-abr-2024
WEB OF SCIENCETM
Citations
14
checked on 28-feb-2024
Page view(s)
284
checked on 19-abr-2024
Download(s)
206
checked on 19-abr-2024
